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Abstract An increased level of apoptotic material and B
cell activation leading to autoantibody production are hall-
marks of systemic lupus erythematoses (SLE). Increased
FAS expression, apoptosis, and CD154-mediated signaling,
enabling T–B cell interaction are involved in the pathogen-
esis of SLE. This study addresses the expression proWle of
CD154 and FAS in the peripheral blood of patients with
SLE, rheumatoid arthritis (RA) and normal healthy control
donors. Surface markers on peripheral blood T and B cells
from patients and healthy control donors were assessed
using Xow cytometry. The expression of CD154 and FAS
were signiWcantly increased in T and B cells of SLE
patients as compared to healthy control donors and RA
patients. In SLE and RA patients, FAS expression strongly
correlated with CD154 expression on T cells, which was
not found in healthy control donors. FAS expression was
also associated with the occurrence of anti-DNA antibod-
ies. We demonstrate high CD154 and FAS expression as a
characteristic feature of SLE. This pattern may reXect
simultaneous activation of apoptosis and activation of B–T
cell interaction in SLE.
Introduction
Systemic lupus erythematoses (SLE) is a systemic autoim-
mune disease characterized by plasma B cells secreting
nuclear autoantibodies [11], especially the pathognomonic
anti-double-stranded DNA autoantibodies (anti-dsDNA). B
and T cell interaction is required for the induction of
humoral immunity. T cells can induce B cell proliferation
and diVerentiation via the ligation of CD154 by CD40 as a
costimulatory molecule. The interaction of T and B cells in
SLE is of major importance for the pathogenesis of the dis-
ease. CD154 hyperexpression in patients with active SLE
was shown on T cells, B cells, and monocytes and corre-
lated with disease activity [4]. Interestingly, not only mem-
brane bound, but also soluble CD154 levels correlate with
disease activity and enhanced titers of anti-dsDNA in
patients with SLE, indicating a central role for the patho-
genesis of CD154 [9]. Underlining the importance of the
CD154–CD40 interaction in SLE, treatment with a mono-
clonal Abs to CD154 signiWcantly decreased disease activ-
ity in SLE patients [3]. However, this treatment is
associated with thromboembolic events [13] as a severe
side eVect leading to the hypothesis that CD154 cross-link-
ing has eVects aside co-stimulation.
An accumulation of apoptotic remnants in the tissue is
observed in a subgroup of patients with SLE. FAS (CD95)
and FAS–ligand interaction are associated with the induc-
tion of apoptosis [7]. The stimulation of autoreactive B
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apoptosis in vitro [8]. In parallel, elevated plasma levels of
sCD154 in patients with SLE increase CD95 expression on
B cells [16]. B cells, stimulated via CD40, are highly sus-
ceptible to FAS-mediated apoptosis [8], when exposed to
FAS-ligand expressing T cells [14]. Consequently, we
hypothesized that the CD154–CD40 mediated interaction
and the upregulation of FAS may occur simultaneously in
SLE. Therefore, we measured the expression of FAS,
CD40, and CD154 on T and B lymphocytes in a cohort of
52 patients with SLE, 32 patients with rheumatoid arthritis
(RA), and 40 normal healthy control donors. The expres-
sion of these surface markers was correlated with each
other and with the clinical course of SLE.
Materials and methods
Patient data
The patient population comprises 52 SLE and 32 RA
patients. All patients were treated with disease modifying
anti-rheumatic drugs (DMARDs) and/or corticosteroids. At
the time of Wrst analysis, all patients had an established dis-
ease. Disease activity diVered, and was assessed by serum
levels of C-reactive protein (CRP), erythrocyte sedimenta-
tion rates [10], and SLE disease activity index (SLEDAI)
score for each patient and the use of medication was
recorded (Table 1). Forty age and sex-matched healthy
donors served as controls. The study was approved by the
University of Erlangen–Nuremberg Institutional Review
Board, and written informed consent was obtained from all
individuals before entering the study.
Immune phenotyping
Whole blood was stained for 30 min with saturating
amounts of directly labeled mAbs. After automated lyses of
the red blood cells (Q-Prep, Beckman Coulter, Cambridge,
MA), the leucocytes were Wxed with 1% paraformaldehyde
and analyzed using Xow cytometry (EPICS, Beckman
Coulter, Cambridge, MA). The following phycoerythrin
(PE), Xuorescein-isothiocyanate (FITC), or CyChrome
(Cy5) conjugated monoclonal antibodies were used: anti-
CD4 (FITC/PE), anti-CD19 (FITC/PE/Cy5) (PE), anti-
CD40 (FITC), anti-CD154 (FITC), and anti-CD95 (PE)
(BD Pharmingen, Heidelberg, Germany). Unlabeled cells
were used as controls for determining background and
autoXuorescence.
Statistical analysis
DiVerences in data distribution were analyzed by two-tailed
Student t tests. Correlation analysis was performed follow-
ing the Pearson test. Comparison of two correlation
analysis was assessed by the MetaAnalysis program 5.3 of
Ralf Schwarzer; http://web.fu-berlin.de/gesund/gesu_engl/
meta_e.htm.
Results
Expression of CD154 in SLE patients in comparison to RA 
and healthy control donors
Since ligation of the costimulatory molecule CD40 on B
cells by its ligand CD154 on T cells plays a central role for
B cell activation, we assessed the expression of both mole-
cules using Xow cytometry. The individual percentages of
CD154 expressing B cells (CD19pos, Fig. 1a) and T helper
cells (CD4pos, Fig. 1b) were signiWcantly increased in
patients with SLE compared with healthy control donors
and patients with RA (B cells) or only compared with
healthy control donors (T helper cells). In detail,
0.6 § 0.7% of B cells from healthy control donors were
positive for CD154, which was comparable to RA patients
(0.6 § 0.8%). In contrast, CD154 expression was signiW-
cantly more frequent (2.1 § 3.2%) in patients suVering
from SLE. Similarly, CD154 expression was also increased
in T helper cells of patients with SLE (1.8 § 3.1%) as com-
pared to healthy control donors (0.6 § 0.8%). The data sug-
gest that expression of the costimulatory molecule CD154
is increased in T and B cells of SLE patients. Thus, an
increased expression of CD154 in B cells also discriminates
SLE patients from other autoimmune diseases such as RA
[12].
Expression of CD40 in SLE patients in comparison to RA 
and healthy control donors
In parallel, we assessed CD40, the ligand of CD154 in
peripheral blood cells of patients with SLE and RA as well
as healthy control donors. CD40 expression was found in
Table 1 Patient data
RA patients 
mean (range)
SLE patients
mean (range)
NHD 
mean (range)
Number 32 52 40
Age 54.6 (27–69) 45.3 (20–72) 36.3 (22–68)
Sex (female/male) 32 f, 9 m 45 f, 7 m 27 f, 13 m
C-reactive protein 0.5 (0–1.5) 2.5 (0.1–17) n.d.
SLEDAI n.a. 4.3 (0–16) n.a.
Anti-DNA n.d. 60.5 (0–1380) n.d
ANA n.d. 1974 (0–10000) n.d.123
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expression in SLE patients (71.9 § 22.9%) than in healthy
control donors (85.4 § 14.1%) and RA patients
(79.2 § 18.6%) (Fig. 1c). Thus, in contrast to the Wndings
made for CD154 expression on SLE patient’s B cells no
discriminative propensity for CD40 expression could be
found among RA patients, healthy donors and SLE
patients.
Expression of FAS in SLE patients in comparison to RA 
and healthy control donors
An accumulation of apoptotic material is observed in vari-
ous tissues of patients with SLE. Since CD154 leads to an
augmented expression of CD95, the expression of this pro-
apoptotic molecule was also analyzed. FAS expression was
increased in B cells (Fig. 2a) and T cells (Fig. 2b) from
patients with SLE in comparison to healthy control donors.
In detail, 38 § 20% of B cells and 66 § 14% of T cells
expressed FAS in SLE patients. In healthy control donors
only 19 § 7% of B cells and 51 § 9% of T cells expressed
FAS. Importantly also RA patients displayed a lower
expression of FAS in B cells (25 § 14%), whereas its
expression in T cells (63 § 13%) was comparable to the
expression in T cells of SLE patients.
Correlation of CD154 and FAS expression
To delineate an association between CD154 and CD95
expression correlation analysis was performed. There was a
signiWcant correlation (r = 0.75; P = 0.001, Fig. 2d)
between the percentages of CD154pos and CD95pos T cells
in patients with SLE. To delineate whether this balance is
similar a correlation analysis was also performed in healthy
control donors. However, the correlation was much less
pronounced (r = 0.35, P = 0.0252, Fig. 2e). In RA patients,
the correlation of CD154pos and CD95pos T cells was simi-
lar as observed in SLE patients (r = 0.72, P = 0.0001, data
not shown). Importantly, the correlations calculated for
SLE and RA patients diVered signiWcantly (P = 0.003) from
the correlation calculated in healthy control donors. Thus,
CD154 and CD95 expression strongly correlate in T cells
of patients with SLE and RA.
Since FAS is associated with the induction of apoptosis
and an increase in apoptotic material is a hallmark of SLE,
we next addressed whether increased FAS expression in
T cells is associated with increased SLE disease activity.
Indeed, patients with SLE and high FAS expression in
T cells also display an increased amount of anti-DNA
antibodies (Fig. 2c).
Discussion
In this study, an increased expression of CD154 and FAS
was denoted in peripheral blood T and B cells of patients
with SLE as compared to healthy control donors. More-
over, the expression of CD154 in B cells and FAS in T and
B cells of SLE was higher than the expression of both mol-
ecules in lymphocytes of RA patients. Moreover, there was
tight correlation observed between CD154 and FAS expres-
sion in SLE and RA. These Wndings lead us to the hypothe-
sis of an altered balance between CD154 and FAS on
T cells in autoimmunity. FAS expression was also associ-
ated with the occurrence of anti-DNA antibodies a good
marker of disease activity in SLE.
In coherence with various other publications, we also
found an increased expression of CD154 on T cells [4] and
B cells [6] in patients with SLE. In contrast to the published
data [4], the increased expression of CD154 did not corre-
late with disease activity as assessed by SLEDAI, but core-
lated to the occurrence of anti-DNA antibodies levels,
which is a surrogate marker for disease activity in SLE
patients. Thus, we assume that CD154 plays an important
role in patients with SLE that might lead to an increase in
clinical disease activity as shown for the correlation of
Fig. 1 CD154 and CD40 expression in SLE: T and B cells were
isolated from full blood by gradient centrifugation. The percentage of
a CD154pos B and b CD4+ T cells and c CD40pos B cells was assessed
using Xow cytometry. All data are represented as dots for every indi-
vidual patient and healthy control donor. Percentages of cells
expressing certain surface markers are demonstrated for patients with
RA and SLE represented on the Wrst and second and such found on
healthy control donors (NHD) on the right column, representatively.
Statistical diVerences were calculated employing the student’s t test123
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rence of anti-DNA antibodies on the other hand.
Treatment with neutralizing antibody against CD154
[13] leads to the occurrence of thromboembolic events.
Because anti-phospholipid antibodies are associated with
vascular events in SLE and of monoclonal antibodies to
CD40 was linked to the anti-phospholipid antibodies in
vivo [2], we analyzed whether increased levels of CD40 of
CD154 expressing cells correlate with anti-phospholipid
antibodies in our cohort. No association could be found
(data not shown).
Autoantibodies against FAS–ligand can be found in 30%
of the patients with SLE. It has been suggested that this
leads to an inhibition of FAS/FAS-L-mediated apoptosis
[15]. In contrast, we demonstrated that the percentage of
FAS expressing cells is increased on lymphocytes of
patients with SLE. Whether this increase in FAS expression
is a reaction on autoreactive anti-FAS antibodies remains
unclear. However, the level of apoptotic material in patients
with SLE is increased. This may be due to a clearance defect
of apoptotic material in patients with SLE [5]. Alternatively,
it could also be associated with an increased induction of
apoptosis [12], potentially mediated by increased expression
of FAS. Since the expression level of FAS correlates with
CD154 and, in parallel, the disease activity, an increase in
disease activity may lead to an increase in apoptosis. In
coherence, an increased expression of CD154 leads to an
increased expression of FAS–ligand and induced, subse-
quently, apoptosis in biliary epithelial cells [1].
In summary, we showed that the expression of CD154
and FAS on SLE patients’ T and B cells was increased and
correlated with each other in tight correlation. FAS expres-
sion was also associated with the occurrence of anti-DNA
antibodies a good marker of disease activity in SLE.
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Fig. 2 CD95 expression in SLE: T and B cells were isolated from full
blood by gradient centrifugation. Percentages of CD95pos cells among
a CD4pos T and b CD19pos T cells were assessed with Xow cytometry.
All data are represented as dots for every individual patient in two
columns. Percentages of cells expressing CD95 are demonstrated for
patients with RA, SLE, and healthy control donors (NHD). Statistical
diVerences were calculated employing the Student’s t test. c Patients
with SLE were separated into two groups: negative (left) and positive
(right) for anti-DNA antibodies. Percentages of CD95pos T cells are
demonstrated for both groups as mean § standard deviation. Statistical
diVerences were calculated employing the Student’s t test. Correlation
analysis of CD154 and CD95 expression on T cells of SLE patients
d and healthy control donors e Every dot represents the individual
expressional percentage found within one patient for CD154 and CD95
on T cells. The correlation line is depicted as a line with the 95%
conWdence interval within the graph123
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